By Kathleen Gallagher, Milwaukee State Journal
Exact Sciences Corp., a Madison maker of molecular diagnostic tests, said Monday its flagship test for colon cancer has been added to a data set that is widely used to measure the quality of health plans.
The test, called Cologuard, is now included in the 2017 Healthcare Effectiveness Data and Information Set quality measures for colorectal cancer screening. More than 90% of all U.S. health plans use the HEDIS information to measure performance on care and service.
“Cologuard’s inclusion in the preeminent quality measures and its standing as an A-graded service in a leading screening guideline are critical steps toward becoming a standard of care for colon cancer screening,” said Kevin Conroy, chairman and chief executive officer of Exact Sciences in a news release.
Quality measures such as those tracked by HEDIS influence the reimbursement levels health care providers receive under value-based health care structures. Providers can now receive quality credit when their patients are screened using Cologuard, Conroy said. Read more …